Search Results for “EC” – Page 262 – media

its hospitals frequently violate the law in advertising, and are repeatedly fined for illegal use of medical insurance funds

Recently, the State Administration for Market Regulation issued a work plan to organize and carry out special actions on advertising supervision in the field of people’s livelihood across the country from April to November 2024. Among them, the first thing to bear the brunt is to maintain a high-pressure and severe crackdown on illegal medical beauty advertising. The document emphasizes that the release of medical beauty advertisements should be strictly regulated, and illegal behaviors such as publishing medical beauty advertisements without advertising review, creating anxiety about appearance, and exaggerating the effects of medical beauty will be severely cracked down on. Seriously investigate and deal with the behavior of platforms, live broadcast rooms, beauty anchors, and celebrities publishing illegal medical beauty advertisements in live broadcast marketing. 　　No.9 Observation will continue to observe the medical beauty industry and the general health industry. Under the strong supervision of the medical beauty industry by ...
- Source: drugdu
- 117
- April 17, 2024
Francis Crick researchers reveal pathways linking intestinal inflammation and colitis

Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis The study, published in Nature Immunology, could help identify new ways to treat inflammatory bowel disease (IBD). Collectively known as IBD, Crohn’s disease and ulcerative colitis are incurable conditions that involve excessive inflammation in the gut and affect over 500,000 people in the UK, according to Crohn’s & Colitis UK. In this study, researchers deleted two proteins, c-Maf and Blimp-1, from T cells in mice to understand their role in maintaining gut health via IL-10. Mutations in the cytokine IL-10 or its receptor can result in IBD in children and it has previously been shown that c-Maf and Blimp-1 can drive the activity of the IL-10 gene in T cells. They found that, when combined with an environmental trigger – an infection with the Helicobacter hepaticus bacterium – IL-10 activity in T cells was reduced and ...
- Source: drugdu
- 79
- April 17, 2024
Novartis, Arvinas Agree to Strategic Collaboration to Develop Treatment for Prostate Cancer

Don Tracy, Associate Editor Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis. Novartis and Arvinas announced that they have agreed to terms on a collaboration to develop and commercialize ARV-766, Arvinas’ advanced Protac androgen receptor degrader designed for prostate cancer treatment. Per terms of the deal, Novartis will focus on worldwide clinical development, commercialization, and will obtain all associated rights for ARV-766 and the AR-V7 program. In turn, Arvinas will receive an upfront payment of $150 million, with the ability to receive up to $1.01 billion based on developmental, regulatory, and commercial milestones, plus royalties on sales of ARV-766. Completion of the deal depends on when regulatory approvals are met, which requires acquiescence with the Hart-Scott-Rodino Act.1 “We are thrilled to partner with an organization that shares our dedication to delivering transformative medicines to patients with significant unmet need,” said John Houston, PhD, ...
- Source: drugdu
- 94
- April 16, 2024
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means that a one-size-fits-all approach often falls short. Individual responses to the same drug can vary dramatically. Personalized cancer treatment, which outperforms traditional treatment methods, increasingly relies on genomics—DNA profiling of a patient’s cancer—to tailor therapy. Current genomic profiling processes can analyze thousands of genes but might take weeks to deliver results and still fail to provide complete clarity on the optimal treatment strategy. For the first time, researchers have combined genetic testing with personalized drug screening directly on tumor samples to identify the right treatment for children with relapsed cancers, offering a timelier and effective approach. The functional precision medicine approach to target cancer has been developed by researchers at Florida International University (Miami, FL, USA) combines genetic testing with a new method of ...
- Source: drugdu
- 98
- April 16, 2024
Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient’s skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues to pathologists who take several days to determine if any cancerous cells remain, leading to a second surgery for removing additional cells in about 20% of cases. Pathologists process these tissues by slicing them into thin sections and staining them with hematoxylin and eosin (H&E), which enhances the visibility of cellular structures and is crucial for diagnosing cancers and other diseases. However, this method is labor-intensive and irreversible; once a biopsy is sliced in one direction, it cannot be resectioned for alternative views. Now, a “virtual biopsy” could allow dermatologists to forego the scalpel and scan the skin to check for cancerous cells without an incision. Similarly, surgeons might soon be able to determine if they ...
- Source: drugdu
- 98
- April 16, 2024
UK charities condemn continued drug shortages

Ahandful of UK charities and community pharmacists urged the UK government to find a fix for the ongoing drug shortage issue to prevent further patient suffering. The UK Epilepsy Society, SUDEP Action, Epilepsy Action and Parkinson’s UK, joined forces to call for a meeting with the Health Secretary, Victoria Atkins. The Association of Independent Multiple Pharmacies (AIMp) found that community pharmacists are spending an average of two hours every day to find patients’ medications due to the disruptions. In a 11 April press release, Dr. Leyla Hannbeck, AIMp’s CEO, said, “The system is overly complex and shrouded in secrecy – what we need is openness and transparency. Pharmacists are in the same position as patients – we are at the end of the supply chain but are the last people to find out about medication shortages. Consequently, we are unable to plan in advance and support the people who rely ...
- Source: drugdu
- 150
- April 16, 2024
FDA approves new administration routes for Xcopri

South Korea-based SK Life Sciences has received US Food and Drug Administration (FDA) approval for two new forms of administration of its epilepsy drug Xcopri (cenobamate), as an oral suspension mixed with water for mouth administration or via a nasogastric tube. Discovered and developed by SK Biopharmaceuticals, Xcopri is an anti-epileptic drug indicated for partial-onset seizures in adults. The therapy reduces repetitive neuronal firing by inhibiting voltage-gated sodium currents, leading to a decreased occurrence of seizures. The oral form of the treatment is taken once daily. The FDA-approved label revision is based on findings from an open-label study comparing the bioequivalence of three ways of administering the medication: swallowing a whole tablet, taking a crushed tablet in water by mouth, and using a nasogastric tube to administer a crushed tablet in water. The approval addresses the needs of patients living with epilepsy, who are unable to swallow Xcopri tablets whole, ...
- Source: drugdu
- 100
- April 16, 2024
Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pancreatic cancer. Orphan drug designations are granted to medicines intended to treat rare conditions and come with benefits such as tax credits for US-based clinical trials and potentially seven years of market exclusivity in the designated indication upon agency approval. Pancreatic cancer is one of the most lethal forms of cancer, with a survival rate beyond ten years of around 5%. CAN-2409 was also granted fast track designation in pancreatic cancer by the FDA in December 2023, meaning the candidate is in line for expedited development and review times. CAN-2409 is an off-the-shelf immunotherapy that is a combination of a genetically modified adenovirus and the herpes simplex virus thymidine kinase (HSV-tk) gene. The drug works by inducing T cell response at both the targeted tumour and at ...
- Source: drugdu
- 71
- April 16, 2024
InterPharma 2024

Organiser: JI EXPO Time:9 – 12 Oct 2024 address：Jl. Gatot Subroto, RT.1/RW.3, Gelora, Tanahabang, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10270,Indonesia Exhibition hall: Balai Sidang Jakarta Convention Center Product range: Apis, intermediates, natural extracts, excipients, formulations, custom manufacturing, biopharmaceuticals, fine chemicals, laboratory equipment, instruments, laboratory appliances, water treatment, environmental and quality control, technical publications, pharmaceutical products, pharmaceuticals, pharmaceutical engineering, materials and packaging, pharmaceutical machinery and equipment About InterPharma： Jakarta Pharmaceutical Exhibition (InterPharma) is the largest and most influential pharmaceutical exhibition in Indonesia. It is one of the important pharmaceutical, pharmaceutical and packaging professional exhibitions in Southeast Asia. It can exhibit the range of apis, intermediates, biopharmaceuticals, medical supplies, material packaging, pharmaceutical machinery and equipment, etc. At the same time, various conferences will be held to discuss the future development trend of the pharmaceutical industry, and the market potential is huge.
- Source: drugdu
- 166
- April 16, 2024
GlobalData

The pharma industry has experienced a notable uptick in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years. These agreements, primarily concentrated in oncology, immunology, and central nervous system therapeutics, have collectively accumulated an impressive $21 billion in deal value. Furthermore, the period from 2020 to 2022 witnessed a remarkable surge in deal worth, particularly in the domain of hematological disorders, reaching a substantial total deal value of $1.8 billion, reveals GlobalData. Ophelia Chan, Business Fundamentals Analyst at GlobalData, comments: “This underscores the increasing significance of CRISPR advancements in the development of therapies for hematological disorders.” The FDA’s approval of Casgevy in December 2023 marked a significant breakthrough in gene therapy. Developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is the first CRISPR and CRISPR-associated protein 9 (Cas9) genome editing therapy for sickle cell disease and beta thalassemia. This ...
- Source: drugdu
- 124
- April 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.